Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
0.08 (1y: -68%)
Market Cap 10.5 M P/E(ttm)
Enterprise Value 10.13 M P/B 1.80
CXM- AMEX (USA)
Cardium Therapeutics, Inc.
Not Rated
Top Ranked Predictable Companies
$0.08
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry		 vs
history
Cash to Debt No Debt
CXM's Cash to Debt is ranked higher than
95% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. CXM: No Debt )
CXM' s 10-Year Cash to Debt Range
Min: 0.27   Max: No Debt
Current: No Debt
Equity to Asset 0.815
CXM's Equity to Asset is ranked higher than
81% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.53 vs. CXM: 0.815 )
CXM' s 10-Year Equity to Asset Range
Min: -0.86   Max: 0.82
Current: 0.82
-0.86
0.82
Interest Coverage No Debt
CXM's Interest Coverage is ranked higher than
95% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CXM: No Debt )
CXM' s 10-Year Interest Coverage Range
Min: No Debt   Max: No Debt
Current: No Debt
F-Score: 1
Z-Score: -21.78
M-Score: 8.28
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry		 vs
history
Operating margin (%) -1068.80
CXM's Operating margin (%) is ranked lower than
119904% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. CXM: -1068.80 )
CXM' s 10-Year Operating margin (%) Range
Min: -2774.6   Max: -101.1
Current: -1068.8
-2774.6
-101.1
Net-margin (%) -1060.3
CXM's Net-margin (%) is ranked lower than
119904% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. CXM: -1060.3 )
CXM' s 10-Year Net-margin (%) Range
Min: -2624.7   Max: -200.3
Current: -1060.3
-2624.7
-200.3
ROE (%) -130.7
CXM's ROE (%) is ranked lower than
119904% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CXM: -130.7 )
CXM' s 10-Year ROE (%) Range
Min: -300.4   Max: -19.7
Current: -130.7
-300.4
-19.7
ROA (%) -106.6
CXM's ROA (%) is ranked lower than
119904% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. CXM: -106.6 )
CXM' s 10-Year ROA (%) Range
Min: -238.9   Max: -14.1
Current: -106.6
-238.9
-14.1
ROC (Joel Greenblatt) (%) -1259.80
CXM's ROC (Joel Greenblatt) (%) is ranked lower than
119904% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CXM: -1259.80 )
CXM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -860133   Max: -27.3
Current: -1259.8
-860133
-27.3
Revenue Growth (%) -33.1
CXM's Revenue Growth (%) is ranked lower than
119904% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CXM: -33.1 )
CXM' s 10-Year Revenue Growth (%) Range
Min: -100   Max: 5.7
Current: -33.1
-100
5.7
EBITDA Growth (%) -38.8
CXM's EBITDA Growth (%) is ranked lower than
119904% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CXM: -38.8 )
CXM' s 10-Year EBITDA Growth (%) Range
Min: -56.3   Max: 102.1
Current: -38.8
-56.3
102.1
EPS Growth (%) -40.3
CXM's EPS Growth (%) is ranked lower than
119904% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CXM: -40.3 )
CXM' s 10-Year EPS Growth (%) Range
Min: -44.7   Max: 18.4
Current: -40.3
-44.7
18.4
» CXM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

CXM Guru Trades in

Q2 2011

CXM Guru Trades in Q2 2011

Ken Fisher Sold Out
Jim Simons Sold Out
» More
Q1 2012

CXM Guru Trades in Q1 2012

Jim Simons 11,193 sh (New)
» More
Q2 2012

CXM Guru Trades in Q2 2012

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CXM



No Insider Trades Found!
» Financial Charts

Peter Lynch Chart

Guru Investment Theses on Cardium Therapeutics, Inc.

Baron Funds Comments on CarMax Inc. - Feb 06, 2013

With $11 billion in sales, CarMax, Inc. (CXM) is the nation's largest retailer of used cars. The company's shares rose after it demonstrated positive momentum in its sales and earnings growth. We believe that several positive factors should set the stage for continued good results in 2013. These include a significantly improved supply of late model cars entering the used car market, which should drive better prices and sales volume; accelerating same store sales as more recently-opened stores enter the sales base; and, pent-up demand for used cars among drivers, resulting from an the high average age of cars currently on the road.

From Baron Funds' fourth quarter letter.


Check out Ron Baron latest stock trades

Top Ranked Articles about Cardium Therapeutics, Inc.

Baron Funds Comments on CarMax Inc.
February 6, 2013
With $11 billion in sales, CarMax, Inc. (CXM) is the nation's largest retailer of used cars. The company's shares rose after it demonstrated positive momentum in its sales and earnings growth. We believe that several positive factors should set the stage for continued good results in 2013. These include a significantly improved supply of late model cars entering the used car market, which should drive better prices and sales volume; accelerating same store sales as more recently-opened stores enter the sales base; and, pent-up demand for used cars among drivers, resulting from an the high average age of cars currently on the road. Read more...

Ratios

vs
industry		 vs
history
P/B 1.80
CXM's P/B is ranked higher than
86% of the 606 Companies
in the Global Biotechnology industry.

( Industry Median: 3.56 vs. CXM: 1.80 )
CXM' s 10-Year P/B Range
Min: 2.27   Max: 64.23
Current: 1.8
2.27
64.23
P/S 7.40
CXM's P/S is ranked higher than
51% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: 7.38 vs. CXM: 7.40 )
CXM' s 10-Year P/S Range
Min: 6.8   Max: 304
Current: 7.4
6.8
304
EV-to-EBIT 76.9
CXM's EV-to-EBIT is ranked lower than
100% of the 244 Companies
in the Global Biotechnology industry.

( Industry Median: 22.58 vs. CXM: 76.9 )
CXM' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 76.9

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 8.7
CXM's Price/Net Cash is ranked higher than
76% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 8.90 vs. CXM: 8.7 )
CXM' s 10-Year Price/Net Cash Range
Min: 6.6   Max: 37.8
Current: 8.7
6.6
37.8
Price/Net Current Asset Value 8.7
CXM's Price/Net Current Asset Value is ranked higher than
75% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: 45.80 vs. CXM: 8.7 )
CXM' s 10-Year Price/Net Current Asset Value Range
Min: 19   Max: 170
Current: 8.7
19
170
Price/Tangible Book 2.9
CXM's Price/Tangible Book is ranked higher than
79% of the 564 Companies
in the Global Biotechnology industry.

( Industry Median: 5.60 vs. CXM: 2.9 )
CXM' s 10-Year Price/Tangible Book Range
Min: 3.9   Max: 28.9
Current: 2.9
3.9
28.9
Price/Median PS Value 0.2
CXM's Price/Median PS Value is ranked lower than
54% of the 550 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. CXM: 0.2 )
CXM' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 4.4
Current: 0.2
0.4
4.4
Forward Rate of Return (Yacktman) -420.12
CXM's Forward Rate of Return (Yacktman) is ranked lower than
119904% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CXM: -420.12 )
CXM' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -227.2   Max: 25.7
Current: -420.12
-227.2
25.7

Business Description

Cardium Therapeutics, Inc. was organized in Delaware in December 2003. Its business is focused on the acquisition and strategic development of product opportunities or businesses having the potential to address significant unmet medical needs, and definable pathways to commercialization, partnering or other monetization following the achievement of corresponding development objectives. The Company's business model is designed to create multiple opportunities for success while avoiding reliance on any single technology platform or product type, and to leverage Cardium's skills in late-stage product development in order to bridge the critical gap between promising new technologies and product opportunities that are ready for commercialization. The product candidate from its Cardium Biologics unit is Generx (alferminogene tadenovec, Ad5FGF-4), which is being developed as a potential treatment for myocardial ischemia (insufficient blood flow within the heart muscle) due to coronary heart disease. Generx represents a new therapeutic class of cardiovascular biologics designed to promote collateral angiogenesis, a natural process of blood vessel growth within the heart muscle, to increase blood supply to ischemic areas of the heart following a one-time intracoronary administration. The Company's Tissue Repair Company subsidiary is focused on the development of therapeutics and devices for the potential treatment of chronic wounds such as non-healing diabetic ulcers and other wounds, as well as the repair of other tissues, including both hard tissue injuries such as bone fracture, as well as soft tissue injuries affecting ligaments, tendons or cartilage. The pharmaceutical, biotechnology and medical device industries are intensely competitive. New drugs, biologics and devices are subject to extensive regulation under the federal Food, Drug, and Cosmetic Act. In addition, biologics are also regulated under the Public Health Service Act.
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:42C.Germany
» More Articles for CXM

Headlines

Articles On GuruFocus.com
Baron Funds Comments on CarMax Inc. Feb 06 2013 
POSITIVE NEWS FLOW Jan 05 2012 
Cardium Therapeutics Inc Reports Operating Results (10-Q) Nov 09 2010 
Cardium Therapeutics Inc Reports Operating Results (10-Q) May 10 2010 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK